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July 10, 2012:166–8with renal impairment; in this context, AGEs may provide the
common pathophysiological link. An increase in AGEs can be
determined fundamentally by 2 factors: the existence of chronic
hyperglycemia and/or a high degree of oxidative stress (3). Al-
though AGEs occur as a result of hyperglycemia, their effects can
occur independently of glycemic control. This finding may explain
the paradoxical progression of diabetic complications in some
patients with comparatively good glycemic control. Results from
the DCCT are consistent with the hypothesis that other factors
such as oxidative stress may be more important mediators of
advanced glycation than hyperglycemia per se in patients already
receiving interventions directed at improving glycemic control.
We introduce the question of whether the relationship between
HbA1c and hs-cTnT is primary or is mediated by AGEs. Perhaps
it would be necessary to conduct a multivariate analysis to consider
whether HbA1c levels predict silent coronary disease regardless of
the levels of AGEs.
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Subclinical Atherosclerosis
and Chronic Troponin Elevation:
The Voice of Silence in Diabetics
We congratulate Rubin et al. (1) on their recent paper entitled
“Chronic Hyperglycemia and Subclinical Myocardial Injury.” In a
large community-based cohort of 9,661 participants without clin-
ically evident coronary artery disease (CAD), the authors demon-
strated that chronic hyperglycemia, as reflected by serum baseline
glycated hemoglobin (HbA1c), is independently associated with
igh-sensitivity cardiac troponin T (hs-cTnT), an established
arker of increased cardiovascular risk. This association was
resent both in subjects with and without diabetes mellitus. The
uthors suggest that a number of factors may contribute to thisssociation, including hyperglycemia-mediated microvascular dys-
unction, oxidative stress, advanced glycation endproducts, myo-
ardial fibrosis, and subclinical atherosclerotic disease.
Herewith, we would like to underscore the importance of silent
therosclerotic disease in those with diabetes, in whom typical
ymptoms of cardiac ischemia are usually masked, even in subjects
ith relevant CAD. Studying consecutive patients who underwent
oronary computed tomography angiography (CCTA) for suspected
AD, we previously reported that hs-cTnT above the 99th percentile
s present in 23% of patients with stable CAD and is related to
laque composition, in particular to noncalcified plaque burden and
ascular remodeling (2). In 168 consecutive patients (21 [12.5%] with
iabetes mellitus), we found that those with diabetes exhibit both
ncreased hs-cTnT levels (9.8 6.3 pg/ml vs. 14.5 7.7 pg/ml; p
0.002) and noncalcified plaque burden (12.1  20.2 mm3 vs. 32.1 
28.6 mm3; p  0.0001) compared with patients without diabetes.
sing multivariate regression analysis, the observed associations of
iabetes with hs-cTnT and noncalcified plaque burden both remained
ndependent after consideration of age, sex, and other atherogenic risk
actors (r  0.24, p  0.007, and r  0.26, p  0.002, respectively).
In patients with acute coronary syndromes, atherosclerotic
laque rupture with subsequent vessel occlusion causes irreversible
yocardial damage. Milder forms of plaque rupture with subse-
uent microembolization of atherothrombotic burden into the
oronary circulation, however, may occur in patients with stable
AD or even in presumably healthy subjects. Thus, more than a
ecade ago, healed plaque destruction was observed in postmortem
tudies (3), whereas angioscopy studies demonstrated that silent
laque rupture is present in 20% of patients with stable CAD
4). Especially in diabetic patients, plaque rupture is expected to
emain subclinical, so that the presence of increased plaque burden
nd troponin leakage in the absence of unstable angina is not
urprising. Furthermore, such plaque microembolization and sub-
equent micronecrosis may subsequently result in the release of
larmin cytokines by stressed cardiomyocytes (5). This may then
licit systemic proinflammatory responses, again contributing to
ascular remodeling processes and microvascular dysfunction, thus
ossibly being part of a vicious circle that encompasses silent
laque rupture, systemic inflammation, and myocardial injury. To
onfirm this hypothesis, the detection by gadolinium-positive
yocardial fibrosis within the perfusion bead of coronary vessels
ith increased noncalcified plaque burden will be decisive in future
iomarker and multimodality imaging studies. Rubin et al. (1)
hould be commended for their comprehensive analysis because
heir study represents an important contribution in the area of
schemic heart disease, considering hs-cTnT as a phenotype for
ncreased cardiovascular risk in those with asymptomatic diabetes.
ow, future studies are warranted to test whether hs-cTnT and
ther biomarkers can be used as therapeutic targets in stable CAD.
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Reply
We thank Dr. Raposeiras-Roubı´n and colleagues for their interest
in our paper (1). They postulate that advanced glycation endprod-
ucts (AGEs) may mediate the association between hyperglycemia
and myocardial damage. We mentioned AGEs as a possible
mechanism that may explain the observed association between
glycated hemoglobin (HbA1c) and high-sensitivity cardiac tro-
onin T (hs-cTnT) in our study. We agree that this is an
nteresting question that deserves further study. Unfortunately, it is
ifficult to obtain tissue AGE measurements in population-based
tudies and, unlike HbA1c, blood AGEmeasurements are not used
clinically.Dr. Farmakis and colleagues express concern that we excluded
participants with a history of coronary heart disease, stroke,
chronic kidney disease, or atrial fibrillation in our study of a
community-based population. These exclusions are important
because hs-cTnT will be elevated in the setting of structural heart
disease and circulating levels may be affected by kidney function.
Stronger associations between HbA1c and hs-cTnT were observed
n the overall study population when no exclusions were applied.
r. Farmakis and colleagues also discuss uncertainty surrounding
he interpretation of slightly elevated troponin levels in the general
opulation. We agree with both Dr. Farmakis and colleagues and
r. Korosoglou and colleagues that additional studies are needed
o understand the potential clinical relevance of new hs-cTnT
ssays.
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